Fulphila

Fulphila is a biosimilar medication containing pegfilgrastim, used to support the immune system during certain medical treatments. It is administered subcutaneously and is manufactured by Biosimilar Collaborations Ireland Limited.

Fulphila is primarily used to help reduce the risk of infections in patients undergoing chemotherapy. It works by stimulating the production of white blood cells, which are crucial for fighting infections. This medication is often prescribed to patients receiving myelosuppressive chemotherapy, helping to maintain their immune system during treatment.

Common effects of Fulphila may include bone pain, which is typically mild to moderate and can be managed with over-the-counter pain relievers. Some patients may also experience fatigue, headache, or mild allergic reactions at the injection site. These effects are generally temporary and should be discussed with a healthcare provider if they persist or worsen.

Fulphila should be handled with care, ensuring proper storage and administration as directed. Patients should inform their healthcare provider about any allergies or medical conditions before starting treatment. It is important to follow the prescribed dosage and administration instructions to minimize the risk of adverse effects.

Fulphila may interact with other medications, particularly those that affect the immune system. Patients should avoid alcohol while using this medication, as it can increase the risk of side effects. It is also important to inform healthcare providers about all current medications, including over-the-counter drugs and supplements, to avoid potential interactions.